Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wesley P Blackaby

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 13, 2005
Pyrazolopyridinones as functionally selective GABAA ligandsWesley P Blackaby, John R Atack, Frances Bromidge, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model SystemXiaojing Wang, Minghua Sun, Connie New, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 2009
Optimisation of a series of potent, selective and orally bioavailable GlyT1 inhibitorsJoanne L Thomson, Wesley P Blackaby, Andrew S R Jennings, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2021
Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β<sub>2</sub> agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)Fabio Rancati, Ian D Linney, Andrea Rizzi, et al.
Neuropharmacology|January 25, 2006
The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagocloneJohn R Atack, Andy Pike, George Marshall, et al.
Bioorganic & Medicinal Chemistry Letters|January 13, 2006
Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligandsWesley P Blackaby, John R Atack, Frances Bromidge, et al.
Genes & Development|June 25, 2021
Targeting the m<sup>6</sup>A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replicationHannah M Burgess, Daniel P Depledge, Letitia Thompson, et al.
Journal of Medicinal Chemistry|June 10, 2024
Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Inhaled Treatment of Respiratory DiseasesLaura Carzaniga, Ian D Linney, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|April 14, 2006
A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxietyRichard T Lewis, Wesley P Blackaby, Timothy Blackburn, et al.
Journal of Medicinal Chemistry|January 6, 2006
Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disordersSimon C Goodacre, Leslie J Street, David J Hallett, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry Letters|September 13, 2005
Pyrazolopyridinones as functionally selective GABAA ligandsWesley P Blackaby, John R Atack, Frances Bromidge, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model SystemXiaojing Wang, Minghua Sun, Connie New, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 2009
Optimisation of a series of potent, selective and orally bioavailable GlyT1 inhibitorsJoanne L Thomson, Wesley P Blackaby, Andrew S R Jennings, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2021
Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β<sub>2</sub> agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)Fabio Rancati, Ian D Linney, Andrea Rizzi, et al.
Neuropharmacology|January 25, 2006
The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagocloneJohn R Atack, Andy Pike, George Marshall, et al.
Bioorganic & Medicinal Chemistry Letters|January 13, 2006
Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligandsWesley P Blackaby, John R Atack, Frances Bromidge, et al.
Genes & Development|June 25, 2021
Targeting the m<sup>6</sup>A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replicationHannah M Burgess, Daniel P Depledge, Letitia Thompson, et al.
Journal of Medicinal Chemistry|June 10, 2024
Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Inhaled Treatment of Respiratory DiseasesLaura Carzaniga, Ian D Linney, Andrea Rizzi, et al.
Journal of Medicinal Chemistry|April 14, 2006
A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxietyRichard T Lewis, Wesley P Blackaby, Timothy Blackburn, et al.
Journal of Medicinal Chemistry|January 6, 2006
Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disordersSimon C Goodacre, Leslie J Street, David J Hallett, et al.
Pageof 2